Kit Simpson to Models, Economic
This is a "connection" page, showing publications Kit Simpson has written about Models, Economic.
Connection Strength
0.968
-
Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya. Value Health. 2011 Dec; 14(8):1048-54.
Score: 0.382
-
Economic modeling of HIV treatments. Curr Opin HIV AIDS. 2010 May; 5(3):242-8.
Score: 0.344
-
Lopinavir/ritonavir versus darunavir plus ritonavir for HIV infection: a cost-effectiveness analysis for the United States. Pharmacoeconomics. 2013 May; 31(5):427-44.
Score: 0.106
-
Timing of elective repeat cesarean delivery at term and neonatal outcomes: a cost analysis. Am J Obstet Gynecol. 2010 Jun; 202(6):632.e1-6.
Score: 0.086
-
A model for estimating the impact of changes in children's vaccines. Am J Public Health. 1995 Dec; 85(12):1666-72.
Score: 0.032
-
Impact of zidovudine-based triple combination therapy on an AIDS drug assistance program. J Acquir Immune Defic Syndr. 2000 Apr 01; 23(4):302-13.
Score: 0.011
-
Modelling the cost effectiveness of lamivudine/zidovudine combination therapy in HIV infection. Pharmacoeconomics. 1997 Jul; 12(1):54-66.
Score: 0.009